Rothschild downgrades Insulet stock rating on competition concerns

The key issue is not near-term demand, but the slope of the adoption curve versus the cost of defending share. PODD has been valued as if it can keep compounding like a category monopolist, yet the next wave of devices appears aimed directly at the product attributes that matter most: wear duration, insulin capacity, and convenience. That makes this less about one-off share loss and more about a margin/marketing treadmill, where every incremental user may require heavier commercial spend and more rebate pressure just to preserve the base.

The market is also underestimating sequencing risk. Competitive devices arriving in late 2026 sound distant, but medtech re-evaluations usually begin 12-18 months earlier as providers, payers, and IDNs line up contracting and formulary decisions. If early Type 2 traction is real, it may not offset the valuation reset because Type 2 expansion typically comes with lower utilization intensity and weaker economics than the core Type 1 franchise, so revenue growth can decelerate even while headline user counts rise.

The contrarian case is that the stock may not be cheap just because it has already derated. A premium multiple on a business facing impending feature competition and recall noise leaves little room for execution slippage, especially with a high gross margin base that invites entrants to undercut on device economics. Near-term upside likely requires either faster-than-expected primary care penetration or proof that the next-generation competitors slip; absent that, the path of least resistance is continued multiple compression rather than a straight-line rebound.